Oxaliplatin

Generic Name
Oxaliplatin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C8H14N2O4Pt
CAS Number
61825-94-3
Unique Ingredient Identifier
04ZR38536J
Background

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...

Indication

Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.

Associated Conditions
Advanced Colorectal Cancer, Stage III Colon Cancer
Associated Therapies
-
Clinical Trials
Related News

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

First Posted Date
2024-01-16
Last Posted Date
2024-12-11
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
250
Registration Number
NCT06205485
Locations
🇺🇸

Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States

🇺🇸

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States

🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 50 locations

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

First Posted Date
2024-01-16
Last Posted Date
2024-03-25
Lead Sponsor
AskGene Pharma, Inc.
Target Recruit Count
780
Registration Number
NCT06206733
Locations
🇨🇳

Beijing cancer hospital, Beijing, China

Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

First Posted Date
2024-01-12
Last Posted Date
2024-01-12
Lead Sponsor
Jinhua Central Hospital
Target Recruit Count
37
Registration Number
NCT06204094
Locations
🇨🇳

Zhejiang University Affiliated Jinhua Hospital, Jinhua, Zhejiang, China

Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

First Posted Date
2024-01-09
Last Posted Date
2024-01-09
Lead Sponsor
Dong Bing Zhao
Target Recruit Count
40
Registration Number
NCT06196554
Locations
🇨🇳

Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/ National Clinical Research for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

First Posted Date
2024-01-09
Last Posted Date
2024-01-09
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
36
Registration Number
NCT06197438

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

First Posted Date
2023-12-20
Last Posted Date
2024-02-28
Lead Sponsor
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Target Recruit Count
486
Registration Number
NCT06177041
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer

First Posted Date
2023-12-12
Last Posted Date
2023-12-12
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
19
Registration Number
NCT06166589
Locations
🇨🇳

Zhongshan Hospital, Shanghai, Shanghai, China

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

First Posted Date
2023-12-04
Last Posted Date
2023-12-14
Lead Sponsor
RemeGen Co., Ltd.
Target Recruit Count
90
Registration Number
NCT06155383
Locations
🇨🇳

Nanfang Hospital, Guangzhou, Guangdong, China

🇨🇳

Shandong Cancer Hospital & Institute, Jinan, Shangdong, China

🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

and more 8 locations

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

First Posted Date
2023-11-18
Last Posted Date
2024-12-20
Lead Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Target Recruit Count
186
Registration Number
NCT06139211
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

First Posted Date
2023-11-09
Last Posted Date
2023-11-13
Lead Sponsor
First Affiliated Hospital of Guangxi Medical University
Target Recruit Count
60
Registration Number
NCT06124378
Locations
🇨🇳

The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy